Publications by authors named "Beth Hahn"

Claim this Profile
tolerates alteration to P66 porin function in a murine infectivity model.
Christa H Fierros, Marie-Line Faucillion, Beth L Hahn, Phillip Anderson, Mari Bonde

Front Cell Infect Microbiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment.
David Salisbury, Jeffrey V Lazarus, Nancy Waite, Clara Lehmann, Sumitra Sri Bhashyam, Beth Hahn

JMIR Public Health Surveill· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of mepolizumab in patients with high-burden severe asthma within a managed care population.
Njira L Lugogo, Michael Bogart, Thomas Corbridge, Elizabeth R Packnett, Joanne Wu, Beth Hahn

J Asthma· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Mepolizumab on Exacerbations in the US Medicare Population.
Sanjay Sethi, Michael Bogart, Thomas Corbridge, Anissa Cyhaniuk, Beth Hahn

J Allergy Clin Immunol Pract· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of amino acid domains of P66 that are surface exposed and important for localization, oligomerization, and porin function of the protein.
Michael W Curtis, Christa H Fierros, Beth L Hahn, Matthew C Surdel, Julie Kessler

Front Cell Infect Microbiol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors leading to discontinuation of biologic therapy in patients with severe asthma.
Jared Silver, Michael Bogart, Nestor A Molfino, James Siddall, Mark Small, Beth Hahn

J Asthma· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling Disease and Economic Burden in CRSwNP Using Machine Learning.
Neil Bhattacharyya, Jared Silver, Michael Bogart, Kalé Kponee-Shovein, Wendy Y Cheng, Beth Hahn

J Asthma Allergy· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematogenous dissemination of pathogenic and non-pathogenic in a short-term murine model of infection.
Matthew C Surdel, Phillip N Anderson, Beth L Hahn, Jenifer Coburn

Front Cell Infect Microbiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous production of the adhesin LIC13411 from pathogenic facilitates binding of non-pathogenic and .
Matthew C Surdel, Beth L Hahn, Phillip N Anderson, Jenifer Coburn

Front Cell Infect Microbiol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.
Thomas B Casale, Autumn Burnette, Arnaud Bourdin, Peter Howarth, Beth Hahn

Ther Adv Respir Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VlsE, the nexus for antigenic variation of the Lyme disease spirochete, also mediates early bacterial attachment to the host microvasculature under shear force.
Xi Tan, Yi-Pin Lin, Michael J Pereira, Mildred Castellanos, Beth L Hahn

PLoS Pathog· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab.
Jonathan Corren, Jared Silver, Nestor A Molfino, Michael Bogart, Elizabeth Packnett, Beth Hahn

Ann Allergy Asthma Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis.
Jared Silver, Nestor Molfino, Michael Bogart, Elizabeth R Packnett, Donna McMorrow, Beth Hahn

Clin Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD.
MeiLan K Han, Riju Ray, Jason Foo, Chaienna Morel, Beth Hahn

NPJ Prim Care Respir Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
Thomas Casale, Nestor A Molfino, Jared Silver, Michael Bogart, Elizabeth Packnett, Beth Hahn

Ann Allergy Asthma Immunol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities.
Ravi Kalhan, David Slade, Riju Ray, Chad Moretz, Guillaume Germain, Beth Hahn

Int J Chron Obstruct Pulmon Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Beth Hahn

BMC Pulm Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating Patients with COPD Receiving Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy.
Chad Moretz, Ashley L Cole, George Mu, Benjamin Wu, Amy Guisinger, Beth Hahn

Int J Chron Obstruct Pulmon Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Chad Moretz, Beth Hahn, John White, Alyssa Goolsby Hunter, Breanna Essoi

Int J Chron Obstruct Pulmon Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital Admission and Readmission Among US Patients Receiving Umeclidinium/Vilanterol or Tiotropium as Initial Maintenance Therapy for Chronic Obstructive Pulmonary Disease.
David Slade, Riju Ray, Chad Moretz, Guillaume Germain, François Laliberté, Beth Hahn

Pulm Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence: Patient views on asthma in respiratory specialist clinics in America.
John Oppenheimer, David J Slade, Beth A Hahn, Laurie Zografos, Alicia Gilsenan

Ann Allergy Asthma Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma.
Jared Silver, Michael Bogart, Elizabeth Packnett, Juan Wu, Donna McMorrow, Beth Hahn

J Asthma Allergy· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BBB07 contributes to, but is not essential for, infection in mice.
Beth Hahn, Phillip Anderson, Zouyan Lu, Rebecca Danner, Zhipeng Zhou

Microbiology (Reading)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
Hector Ortega, Beth Hahn, Michael Bogart, Christopher F Bell, Tim Bancroft

Allergy Asthma Proc· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
Jean-Pierre Llanos, Hector Ortega, Michael Bogart, Elizabeth R Packnett, Janna Manjelievskaia, Beth Hahn

J Asthma Allergy· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis